Delivery Order SPE2DB25D3022-SPE2DB25FWCCQ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,041.38 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order was awarded on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract utilized competitive procurement procedures with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This non-set-aside, competitively awarded contract is valued at $7,308.92 with firm fixed pricing and a completion date of July 29, 2025. The delivery order is issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a delivery order valued at $28,014.24 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and represents a non-set-aside, competitively awarded contract. The work is performed at AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $9,166.50 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This contract type represents a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at...
- The Defense Logistics Agency awarded a $2,416.05 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 29, 2025. This non-competitive delivery order was placed against AmerisourceBergen's broader pharmaceutical supply contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune...
- The Defense Logistics Agency awarded a delivery order valued at $16,204.30 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania—the...
- The Defense Logistics Agency awarded a delivery order valued at $5,543.70 to AmerisourceBergen Drug Corp for the supply of Humira Pen 40 mg/0.8 mls, a pharmaceutical product used to treat inflammatory conditions. This competitively awarded, firm fixed-price contract was issued on July 22, 2025, with an ultimate completion date of July 23, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product for treating inflammatory conditions. This competitively awarded, firm fixed-price delivery order was issued on July 23, 2025, with an ultimate completion date of July 24, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open...
- The Defense Logistics Agency awarded a $5,126.79 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. The contract, which is not set-aside, carries a firm fixed price and is scheduled for completion by August 4, 2025, with performance to be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies, valued at $4,531.80 under a firm fixed price contract. The award, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-competitive delivery order executed without set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform all work at its corporate office location in the...
- SPE2DB25D3022Indefinite Delivery Contract
- SPE2DB25D3022-SPE2DB25FWCCQDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA(CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and was competitively awarded without set-aside designation. Performance will take place at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. Through this prime contract, AmerisourceBergen supplies a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. The delivery order reflects the company's ongoing role as a critical pharmaceutical distributor within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/1/25 |